Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1994 Sep;120(9):550–552. doi: 10.1007/BF01221033

Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule

Vittorio Gebbia 1,2,✉, Roberto Valenza 1,2, Antonio Testa 1,2, Carmelo Sciume 3,2, Antonio Longo 3,2, Calogero Cipolla 4,2, Nicola Borsellino 1,2, Pietro Leo 3,2, Mario Latteri 4,2, Matteo Florena 4,2, Nicola Gebbia 1,2
PMCID: PMC12200607  PMID: 8045920

Abstract

A phase II trial of etoposide (100 mg/m2) on days 4, 5, 6, doxorubicin (Adriamycin, 20 mg/m2) on days 1, 7, and cisplatin (30 mg/m2) on days 2, 8 (EAP) was carried out in order to reduce toxicity associated with a full-dose EAP regimen for advanced and/or metastatic gastric adenocarcinoma. Out of 21 evaluable patients, 2 (10%) had a complete response (CR), 7 (33%) had a partial response (PR), 4 (20%) showed no change and 8 progressed (38%). The mean duration of response (CR+PR) was 8.4+ months. Survival of the whole group was 7.5+ months. Treatment was quite well tolerated by most patients on an outpatient basis. Grade 3 vomiting and leukopenia were seen in 30% and 35% of cases respectively. One patient had grade 3 esophagitis, and 1 patient was hospitalized for severe grade 4 febrile leukopenia. Although the EAP regimen cannot be considered a standard therapy for gastric cancer, the EAP schedule employed in this study seems to be better tolerated than those reported by other authors, and can sefely be given on an outpatient basis.

Key words: Gastric cancer, Chemotherapy, EAP

References

  1. Gastrointestinal Tumor Study Group (1984) Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 53:13–17 [DOI] [PubMed] [Google Scholar]
  2. Haim N, Cohen Y, Honigman J, Robinson E (1982) Treatment of advanced gastric carcinoma with 5-fluorouracil, Adriamycin, and mitomycin C (FAM). Cancer Chemother Pharmacol 8:277–280 [DOI] [PubMed] [Google Scholar]
  3. Katz A, Gansl R, Simon S, et al. (1989) Phase II trial of VP16 (V), Adriamycin (A), and cisplatinum (C) in patients (pts) with advanced gastric cancer (ACG). Proc Am Soc Clin Oncol 8:98 [Google Scholar]
  4. Kelsen D, Atiq OT, Saltz L, et al (1992) FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10:541–548 [DOI] [PubMed] [Google Scholar]
  5. Klein HO, Dias Wickramanayake P, Farrokh GH, et al (1986) 5-Fluorouracil (FU), Adriamycin (ADM) and methotrexate (MTX)-a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Am Soc Clin Oncol 5:84 [Google Scholar]
  6. Le Chevalier T, Smith FP, Harter WK, Schein PS (1985) Chemotherapy and combined modality therapy for locally advanced and metastatic gastric carcinoma. J Clin Oncol 12:46–53 [PubMed] [Google Scholar]
  7. Lerner A, Gonin R, Steele GD, Mayer RJ (1992) Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial. J Clin Oncol 10:536–540 [DOI] [PubMed] [Google Scholar]
  8. McDonald JS, Gohman JJ (1988) Chemotherapy of advanced gastric cancer: present status, future prospects. Semin Oncol 15:42–49 [PubMed] [Google Scholar]
  9. McDonald JS, Schein PS, Wooley PV, et al (1990) 5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 93:533–536 [DOI] [PubMed] [Google Scholar]
  10. O'Connell MJ (1992) Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric cancer: an old lesson rivisited. J Clin Oncol 10:515–516 [DOI] [PubMed] [Google Scholar]
  11. Preusser P, Wilke H, Achterrath W, et al (1989) Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7:1310–1317 [DOI] [PubMed] [Google Scholar]
  12. Schabel FM, Trader MW, Laster WR, et al (1979)cis-Dichlorodiammine-platinum (II): combination chemotherapy and crossresistance studies with tumor of mice. Cancer Treat Rep 63:1459–1473 [PubMed] [Google Scholar]
  13. Sparano JA, Schwartz EL, Salva KM, et al (1990) Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer. Am J Clin Oncol 13:374–378 [DOI] [PubMed] [Google Scholar]
  14. Taguchi T (1989) Combination chemotherapy with etoposide (E), adriamycin (A), and cisplatin (P) (EAP) for advanced gastric cancer. Proc Am Soc Clin Oncol 8:108 [Google Scholar]
  15. Taal BG, Bokkel Huinink WW ten, Franklin H, et al (1990) EAP in advanced gastric cancer. J Clin Oncol 8:939–940 [DOI] [PubMed] [Google Scholar]
  16. WHO/UICC (1979) Handbook for reporting results of cancer treatment. WHO Offset Publ 48
  17. Wilke H, Preusser P, Fink U, et al (1989) Preoperative chemotherapy in locally advanced and non resectable gastric cancer. J Clin Oncol 7:1318–1326 [DOI] [PubMed] [Google Scholar]
  18. Wils JA (1987) Current status of chemotherapy for advanced gastric cancer. Anticancer Res 7:755–760 [PubMed] [Google Scholar]
  19. Wils J, Bleiberg H, Blijham G, et al (1986) An EORTC gastrointestinal group evaluation of the combination of sequential methotrexate (MTX), and 5-fluorouracil (F), combined with adriamycin (A) (FAMTX) in advanced measurable gastric cancer. J Clin Oncol 4:1799–1803 [DOI] [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES